Overall survival in patients with acute lymphoblastic leukemia treated with CALGB 8811 protocol in low income country
DOI:
https://doi.org/10.46765/2675-374X.2021v2n2p95Keywords:
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Stem Cell Transplantation, CALGB8811 protocolAbstract
Introduction: ALL is known to have a lower survival rate in adults and this can be attributed, among other aspects, to intolerance to intensive regimens. As the treatment of ALL is very complex, with many protocols available, this study proposes an analysis regarding the CALGB 8811 protocol in a tertiary health unit in Ceará
Methods: In this retrospective study, 50 patients with a recent diagnosis of ALL who underwent the CALGB8811 protocol were evaluated. Disease risk criteria were based on the CALGB8811 protocol.
Results: CR was obtained in 86% of patients. 12% of patients died during induction due to infectious complications. 30% of patients underwent alloSCT, 60% were on CR1.
The median overall survival (OS) was 21.5 months (8.1-38.7). The 5 years OS was 25% in the transplanted patients versus 60% in the transplanted group. Achieving complete remission after induction chemotherapy and allogeneic hematopoietic stem cell transplantation were the factors associated with better long-term survival rates in uni and multivariate analysis.
Conclusion: Risk factors classically associated with worse adult ALL outcome and post-induction MRD status were not outcome predictors, in addition, post-induction remission and alloSCT were factors associated with a favorable outcome.
Downloads
Published
How to Cite
Issue
Section
License
License and Copyright Policy
The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.
-
License
- All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
- This license permits anyone to:
- Share: Copy and redistribute the material in any medium or format.
- Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
- The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.
More information about the license can be found here: Creative Commons Attribution 4.0 International License.
-
Authors’ Rights
- Authors retain the copyright to their work.
- Authors grant JBMTCT the right to publish the work and make it openly accessible online.
- Authors are free to:
- Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
- Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.
-
No Embargo
- There is no embargo period; articles are made freely available immediately upon publication.
-
Ethical Use
- Users of JBMTCT articles must ensure proper citation of the authors and the journal.
- Articles must not be used in ways that violate ethical or legal standards.
-
Disclaimer
- While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.
For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br
JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.
